First Time Loading...

FRONTEO Inc
TSE:2158

Watchlist Manager
FRONTEO Inc Logo
FRONTEO Inc
TSE:2158
Watchlist
Price: 605 JPY 0.33% Market Closed
Updated: May 19, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

8.5B
-4%
Assets
Growth Rates:
1 Year
-15%
3 Years
-25%
5 Years
-38%
7 Years
-48%
10 Years
+64%
3.8B
-1%
Liabilities
Growth Rates:
1 Year
-13%
3 Years
-48%
5 Years
-58%
7 Years
-69%
10 Years
+170%
4.7B
-7%
Equity
Growth Rates:
1 Year
-17%
3 Years
+19%
5 Years
+1%
7 Years
+13%
10 Years
+24%

Balance Sheet Decomposition
FRONTEO Inc

8.5B
Assets
3.8B
Liabilities
8.5B
Assets
3.8B
Liabilities
Current Assets 3.2B
Cash & Short-Term Investments 1.6B
Receivables 1.3B
Other Current Assets 398.8m
Non-Current Assets 5.2B
Long-Term Investments 896.4m
PP&E 446.7m
Intangibles 3.7B
Other Non-Current Assets 192.8m
Current Liabilities 2.6B
Accounts Payable 32.9m
Accrued Liabilities 91m
Short-Term Debt 1.1B
Other Current Liabilities 1.4B
Non-Current Liabilities 1.2B
Long-Term Debt 1.1B
Other Non-Current Liabilities 117.1m

Balance Sheet
FRONTEO Inc

Rotate your device to view
Balance Sheet
Currency: JPY
Mar-2014 Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022 Mar-2023
Assets
Cash & Cash Equivalents
1 486
2 726
1 799
4 536
5 131
3 926
1 572
3 005
3 461
1 476
Cash Equivalents
1 486
2 726
1 799
4 536
5 131
3 926
1 572
3 005
3 461
1 476
Total Receivables
873
1 544
2 826
3 154
2 550
2 582
2 458
1 966
1 753
1 538
Accounts Receivables
873
1 544
2 826
3 154
2 550
2 582
2 458
1 966
1 753
984
Other Receivables
0
0
0
0
0
0
0
0
0
554
Inventory
7
7
9
73
41
4
4
5
27
38
Other Current Assets
393
345
807
1 270
359
351
674
566
700
612
Total Current Assets
2 760
4 623
5 441
9 034
8 080
6 863
4 708
5 541
5 941
3 663
PP&E Net
671
783
1 105
1 177
763
743
648
1 164
709
427
PP&E Gross
671
783
1 105
1 177
763
743
648
1 164
709
427
Accumulated Depreciation
514
791
1 033
1 104
1 214
1 454
1 457
1 377
1 478
953
Intangible Assets
942
1 407
3 140
3 026
2 577
2 805
2 760
2 733
2 781
2 680
Goodwill
0
169
2 189
2 001
1 807
1 734
1 549
1 423
1 403
1 346
Long-Term Investments
373
512
640
500
849
872
608
888
853
905
Other Long-Term Assets
143
147
401
420
389
425
187
194
138
125
Other Assets
0
169
2 189
2 001
1 807
1 734
1 549
1 423
1 403
1 346
Total Assets
4 889
N/A
7 642
+56%
12 916
+69%
16 159
+25%
14 465
-10%
13 443
-7%
10 462
-22%
11 943
+14%
11 825
-1%
9 145
-23%
Liabilities
Accounts Payable
62
92
358
513
144
138
118
169
64
36
Accrued Liabilities
92
165
116
154
16
35
158
159
126
137
Short-Term Debt
0
36
52
1 000
1 500
1 100
1 600
1 400
0
500
Current Portion of Long-Term Debt
275
457
720
798
961
2 184
3 003
1 251
1 191
925
Other Current Liabilities
360
697
2 255
1 232
1 518
1 291
1 112
1 067
1 220
611
Total Current Liabilities
788
1 448
3 500
3 697
4 139
4 747
5 990
4 047
2 600
2 209
Long-Term Debt
438
773
3 812
6 089
5 294
3 475
761
2 978
2 555
1 662
Deferred Income Tax
66
116
841
758
195
168
62
119
141
132
Minority Interest
21
13
19
32
39
50
66
0
0
0
Other Liabilities
64
84
105
597
483
430
339
154
89
92
Total Liabilities
1 377
N/A
2 434
+77%
8 278
+240%
11 173
+35%
10 151
-9%
8 870
-13%
7 217
-19%
7 299
+1%
5 384
-26%
4 095
-24%
Equity
Common Stock
1 095
1 688
1 706
2 482
2 507
2 559
2 569
2 974
3 035
3 042
Retained Earnings
1 357
1 632
1 428
308
462
448
1 552
1 229
8
1 924
Additional Paid In Capital
883
1 476
1 493
2 266
2 292
2 343
2 353
2 711
2 772
2 779
Unrealized Security Profit/Loss
144
240
0
273
514
530
381
575
549
585
Treasury Stock
0
0
0
0
0
0
0
0
0
0
Other Equity
33
171
287
342
537
412
506
387
93
568
Total Equity
3 512
N/A
5 207
+48%
4 638
-11%
4 986
+8%
4 314
-13%
4 572
+6%
3 244
-29%
4 644
+43%
6 441
+39%
5 050
-22%
Total Liabilities & Equity
4 889
N/A
7 642
+56%
12 916
+69%
16 159
+25%
14 465
-10%
13 443
-7%
10 462
-22%
11 943
+14%
11 825
-1%
9 145
-23%
Shares Outstanding
Common Shares Outstanding
34
35
36
38
38
38
38
39
39
39

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.